David Donovan joined Roswell Park Cancer Institute (RPCI) in 2015. As the Senior Executive Director for New Business Development at Roswell Park, Mr. Donovan provides oversight and strategic leadership to the Institute's current international collaborative partnerships, and continues to assess opportunities to further extend RPCI's mission.
Donovan also co-founded Global Biotechnology and Cancer Therapeutics (GBCT), a for-profit subsidiary company of Roswell Park. In his role as Chief Operating Officer, Donovan oversees the day-to-day operations. GBCT serves as a gateway for Roswell Park to market the many core services available on campus; he works to align and bridge the various novel research at RPCI to market commercialization; and works with varying-sized biotechnology companies, from start-up to publicly traded, who are developing innovative technologies to further Roswell Park's core mission of understanding, preventing and curing cancer.
Mr. Donovan brings over 20 years of experience in health care. He has held senior level marketing, sales, product management and operations positions for Pfizer, Bayer and Abbott Labs. In his most recent position before joining Roswell Park, Mr. Donovan was the Chief Sales Officer at Independent Health.
Mr. Donovan is a 1991 graduate of Allegheny College, graduating Cum Laude, with a dual degree in Biochemistry Engineering and Business Management. He is also a graduate of the University Of Chicago Kellogg School Of Management, Executive Master’s Program in Public Health, Business and Outcomes.